cells

an Open Access Journal by MDPI

IMPACT FACTOR 5.1

Indexed in: PubMed

CITESCORE 9.9

CD4+ T Cells in Antitumor Immunity

Guest Editor:

Dr. Zhi-Chun Ding
Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA

Deadline for manuscript submissions:
closed (10 May 2022)

Message from the Guest Editor

Cancer immunotherapy is emerging as a revolutionary cancer treatment that engages the immune system to eliminate tumor cells. Given the central role of T cells in tumor eradication, multiple T cell-based therapies, such as immune checkpoint blockade (ICB) and adoptive T cell therapy (ACT), have been developed to treat cancer patients in clinics. While most immunotherapies focus on harnessing cytotoxic $CD8^+$ T cells, mounting evidence indicates that $CD4^+$ T cells are increasingly recognized as a critical cornerstone of effective antitumor immunity by orchestrating a broad spectrum of immune cells, including $CD8^+$ T cells, natural killer (NK) cells, and macrophages. The major barriers to effective $CD4^+$ T cell immunotherapy include tumor-induced tolerance featured by hypo-proliferation and an inability to produce effector cytokines, the immunologically "cold" tumor microenvironment (TME) devoid of immune infiltration, and loss of function (exhaustion) in the face of persistent antigenic stimulation. Therefore, there is an urgent demand for novel strategies that can overcome these barriers to potentiate $CD4^+$ T cell immunotherapy.

cells

IMPACT FACTOR 5.1 | Indexed in: PubMed | CITESCORE 9.9

an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Contact Us

Cells Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cells
cells@mdpi.com
𝕏@Cells_MDPI